Quince Therapeutics financials
$31.17+7.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$58.1M | -$57.3M | -$34.6M | -$52.0M |
| Net income | -$84.0M | -$56.8M | -$31.4M | -$51.7M |
| Net margin | — | — | — | — |
| Diluted EPS | $-336.00 | $-262.00 | $-168.00 | $-308.00 |
| EBITDA | -$57.9M | -$40.0M | -$28.4M | -$51.0M |
| Operating cash flow | -$41.4M | -$31.9M | -$18.3M | -$44.0M |
| Free cash flow | -$41.8M | -$32.2M | -$18.5M | -$44.2M |
| Diluted shares | 0.3M | 0.2M | 0.2M | 0.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $5.8M | $6.2M | $20.8M | $44.6M |
| Short-term investments | $11.9M | $34.6M | $54.3M | $45.6M |
| Total debt | $18.0M | $14.3M | $13.4M | $0.00 |
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.3M |
| Shareholders' equity | -$35.7M | $30.1M | $85.1M | $100.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology